Simulations Plus IncNASDAQ:SLP
- LAST PRICE47.7100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots42.9000/ 2
- Ask / Lots76.3300/ 2
- Open / Previous Close0.0000 / 47.7100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLP |
|---|---|---|
| 09:32 ET | 298 | 47.54 |
| 09:56 ET | 204 | 47.135 |
| 09:57 ET | 100 | 47.13 |
| 10:14 ET | 1100 | 47.605 |
| 10:15 ET | 100 | 47.96 |
| 10:21 ET | 1390 | 47.57 |
| 10:30 ET | 900 | 47.565 |
| 10:33 ET | 100 | 47.531 |
| 10:44 ET | 100 | 47.36 |
| 10:46 ET | 1100 | 47.305 |
| 11:00 ET | 118 | 47.2324 |
| 11:33 ET | 500 | 47.65 |
| 11:36 ET | 100 | 47.505 |
| 11:56 ET | 300 | 47.485 |
| 12:14 ET | 470 | 47.5 |
| 12:34 ET | 200 | 47.495 |
| 12:36 ET | 1000 | 47.55 |
| 12:38 ET | 100 | 47.58 |
| 12:45 ET | 1000 | 47.6 |
| 12:54 ET | 197 | 47.535 |
| 01:12 ET | 252 | 47.685 |
| 01:35 ET | 100 | 47.72 |
| 02:08 ET | 100 | 47.9 |
| 02:11 ET | 100 | 47.815 |
| 02:13 ET | 100 | 47.93 |
| 02:20 ET | 200 | 47.87 |
| 02:29 ET | 100 | 47.94 |
| 02:40 ET | 100 | 48.1 |
| 02:45 ET | 2700 | 47.87 |
| 02:49 ET | 200 | 47.86 |
| 02:51 ET | 900 | 47.95 |
| 02:58 ET | 100 | 47.93 |
| 03:02 ET | 1100 | 48.075 |
| 03:21 ET | 465 | 47.97 |
| 03:23 ET | 100 | 47.97 |
| 03:30 ET | 200 | 48 |
| 03:32 ET | 100 | 48.075 |
| 03:36 ET | 200 | 48.16 |
| 03:38 ET | 200 | 48.17 |
| 03:41 ET | 500 | 48.1 |
| 03:48 ET | 200 | 48.1 |
| 03:50 ET | 100 | 48.12 |
| 03:52 ET | 300 | 48.13 |
| 03:54 ET | 200 | 48.06 |
| 03:56 ET | 840 | 47.88 |
| 03:57 ET | 100 | 47.76 |
| 03:59 ET | 100 | 47.71 |
Jun 20, 2024
Simulations Plus to Participate in the Morgan Stanley 3(rd) Annual Life Sciences AI Summit, from 8:30AM ET on Thursday Jun 20, 2024 by Dow Jones
8:30AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 18, 2024
Press Release: Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date, from 8:30AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:30AM ET on Tuesday Jun 18, 2024 by Dow JonesSimulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date, from 8:30AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:30AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 13, 2024
DJ Simulations Plus Is Maintained at Buy by Craig-Hallum, from 9:16AM ET on Thursday Jun 13, 2024 by Dow Jones
9:16AM ET on Thursday Jun 13, 2024 by Dow JonesDJ Simulations Plus Is Maintained at Outperform by Oppenheimer, from 7:26AM ET on Thursday Jun 13, 2024 by Dow Jones
7:26AM ET on Thursday Jun 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Simulations Plus Inc | 953.5M | 92.2x | +3.18% |
Coretag Inc | 1.1B | -13.1x | --- |
Standard BioTools Inc | 610.4M | -1.7x | --- |
MaxCyte Inc | 427.6M | -11.6x | --- |
Pulse Biosciences Inc | 553.4M | -12.3x | --- |
Butterfly Network Inc | 197.3M | -1.6x | --- |
Company Information
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
Contact Information
- Headquarters
- 42505 10Th Street WestLANCASTER, CA, United States 93534-7059
- Phone
- 661-723-7723
- Fax
- 661-723-5524
Executives
- Chairman of the Board
- Walter Woltosz
- Chief Executive Officer
- Shawn O'Connor
- Chief Financial Officer, Chief Operating Officer, Secretary
- William Frederick
- President - PBPK, Regulatory Strategies, Cheminformatics Solutions
- John Dibella
- President - Clinical Pharmacology and Pharmacometric Services
- Jill Fiedler-Kelly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $953.5M |
|---|---|
Revenue (TTM) | $64.7M |
Shares Outstanding | 20.0M |
Dividend Yield | 0.50% |
Annual Dividend Rate | 0.2400 USD |
Ex-Dividend Date | 04-26-24 |
Pay Date | 05-06-24 |
Beta | 0.71 |
EPS | $0.52 |
Book Value | $8.53 |
P/E Ratio | 92.2x |
Price/Sales (TTM) | 14.7 |
Price/Cash Flow (TTM) | 64.9x |
Operating Margin | 12.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
